Astrazeneca PLC (AZN) Downgraded by Vetr Inc.

Vetr cut shares of Astrazeneca PLC (NYSE:AZN) from a buy rating to a hold rating in a research report sent to investors on Monday morning. The firm currently has $29.50 target price on the stock.

Several other equities analysts also recently weighed in on the stock. Deutsche Bank AG reissued a buy rating on shares of Astrazeneca PLC in a research note on Friday, November 11th. Beaufort Securities reissued a hold rating on shares of Astrazeneca PLC in a research note on Friday, November 11th. Bank of America Corporation reissued a buy rating and issued a $41.37 price target on shares of Astrazeneca PLC in a research note on Thursday, November 10th. J P Morgan Chase & Co reissued a neutral rating on shares of Astrazeneca PLC in a research note on Tuesday, December 13th. Finally, Shore Capital reissued a hold rating on shares of Astrazeneca PLC in a research note on Thursday, November 10th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. Astrazeneca PLC presently has an average rating of Buy and an average target price of $34.44.

Shares of Astrazeneca PLC (NYSE:AZN) opened at 29.53 on Monday. The firm’s 50 day moving average price is $27.88 and its 200 day moving average price is $30.06. The stock has a market cap of $74.71 billion, a P/E ratio of 21.40 and a beta of 0.77. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.04.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, February 2nd. The company reported $1.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.62. The business had revenue of $5.59 billion for the quarter, compared to the consensus estimate of $5.43 billion. Astrazeneca PLC had a net margin of 15.21% and a return on equity of 34.30%. The company’s revenue was down 12.7% compared to the same quarter last year. During the same period last year, the firm posted $0.94 earnings per share. On average, analysts expect that Astrazeneca PLC will post $1.82 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Astrazeneca PLC (AZN) Downgraded by Vetr Inc.” was first published by sleekmoney and is the property of of sleekmoney. If you are reading this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be viewed at http://sleekmoney.com/astrazeneca-plc-azn-downgraded-by-vetr-inc/1658210.html.

The firm also recently disclosed a semiannual dividend, which will be paid on Monday, March 20th. Investors of record on Friday, February 17th will be issued a $0.95 dividend. This represents a dividend yield of 6.81%. The ex-dividend date is Wednesday, February 15th. Astrazeneca PLC’s dividend payout ratio (DPR) is currently 49.64%.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Capital International Investors increased its position in shares of Astrazeneca PLC by 0.6% in the third quarter. Capital International Investors now owns 20,600,179 shares of the company’s stock worth $676,922,000 after buying an additional 126,700 shares in the last quarter. Primecap Management Co. CA increased its position in shares of Astrazeneca PLC by 17.4% in the second quarter. Primecap Management Co. CA now owns 15,365,950 shares of the company’s stock worth $463,898,000 after buying an additional 2,281,675 shares in the last quarter. BlackRock Investment Management LLC increased its position in shares of Astrazeneca PLC by 12.1% in the third quarter. BlackRock Investment Management LLC now owns 8,079,111 shares of the company’s stock worth $265,480,000 after buying an additional 872,075 shares in the last quarter. Epoch Investment Partners Inc. increased its position in shares of Astrazeneca PLC by 1.8% in the third quarter. Epoch Investment Partners Inc. now owns 7,935,629 shares of the company’s stock worth $260,765,000 after buying an additional 137,571 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Astrazeneca PLC by 57.5% in the third quarter. Wells Fargo & Company MN now owns 3,365,503 shares of the company’s stock worth $110,589,000 after buying an additional 1,228,331 shares in the last quarter. Hedge funds and other institutional investors own 12.90% of the company’s stock.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

To view Vetr’s full report, visit Vetr’s official website.

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/astrazeneca-plc-azn-downgraded-by-vetr-inc/1658210.html

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *